TY - JOUR
T1 - Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice
T2 - A report of five patients and literature review
AU - Terao, Toshiki
AU - Tsushima, Takafumi
AU - Miura, Daisuke
AU - Ikeda, Daisuke
AU - Fukumoto, Ami
AU - Kuzume, Ayumi
AU - Tabata, Rikako
AU - Narita, Kentaro
AU - Takeuchi, Masami
AU - Matsue, Kosei
N1 - Funding Information:
The authors would like to thank the residents of the Department of Hematology/Oncology for their medical care of patients. We also thank Dr. Tomo Suzuki (Department of Nephrology, Kameda Medical Center) for his excellent advice regarding kidney pathology and Editage (www.editage.jp) for their English language editing services.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Carfilzomib (Cfz) is widely used to treat multiple myeloma. However, real-world data of the incidence of thrombotic microangiopathy (TMA) caused by Cfz is inconsistent (<1–5%). We evaluated 96 consecutive patients who received Cfz to evaluate the incidence of TMA in clinical practice. TMA developed in five patients (5.2%) who were mainly receiving high-dose Cfz (≥56 mg/m2). Based on a literature review, precaution should be taken for Cfz-induced TMA in male patients receiving high-dose Cfz irrespective of the combination therapy, Cfz administration period, and complement level. In conclusion, Cfz-induced TMA might be underestimated in clinical practice, and early intervention should be considered.
AB - Carfilzomib (Cfz) is widely used to treat multiple myeloma. However, real-world data of the incidence of thrombotic microangiopathy (TMA) caused by Cfz is inconsistent (<1–5%). We evaluated 96 consecutive patients who received Cfz to evaluate the incidence of TMA in clinical practice. TMA developed in five patients (5.2%) who were mainly receiving high-dose Cfz (≥56 mg/m2). Based on a literature review, precaution should be taken for Cfz-induced TMA in male patients receiving high-dose Cfz irrespective of the combination therapy, Cfz administration period, and complement level. In conclusion, Cfz-induced TMA might be underestimated in clinical practice, and early intervention should be considered.
KW - Carfilzomib
KW - multiple myeloma
KW - thrombotic microangiopathy
UR - http://www.scopus.com/inward/record.url?scp=85129200065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129200065&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2057485
DO - 10.1080/10428194.2022.2057485
M3 - Article
C2 - 35373680
AN - SCOPUS:85129200065
SN - 1042-8194
VL - 63
SP - 1102
EP - 1110
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -
